To combat the resistance to new drugs developed among individuals with HER2 mutations, researchers have recently developed a new drug-duo that effectively halts cancer cell proliferation in such individuals. Patients with HER2 mutations are treated with neratinib, but an effective way to redress the resistance to neratinib is with everolimus, a TORC1 inhibitor. The drug exerts its effects by inhibiting the TORC1 pathway, which is the epicenter of the development of drug resistance in breast and other cancers.
Currently, everolimus allows patients to benefit from neratinib inhibition of HER2. The drug is a ray of hope for people with resistance against tyrosine kinase inhibitor anti-cancer drugs, fabricating real differences for breasts, ovarian, lung, and other cancer patients harboring HER2 mutations. Source: The Economic Times
